Gilead fourth-quarter hepatitis C drug sales plummet, sees further slowdown

(Reuters) - Gilead Sciences Inc on Tuesday said fourth-quarter sales of its flagship hepatitis C drugs fell by more than half amid increased competition, and the company forecast a further slowdown for the current year.